Dr. Sara Hurvitz of UCLA (left) stands with Dikla Benzeevi to honor her for 17 years of living with breast cancer.
Results of this trial were released at the San Antonio Breast Cancer Symposium and published in the New England Journal of Medicine. The drug, for now labeled DS-8201, was tested in 184 patients. Tumors shrank in 61% of the patients, and disappeared in 6%.
See the full story and video from CBS Evening News. Benzeevi has been an active member of the CTSI Patient Advocacy Board since it was established in 2016.